Dean, School of Basic Medical Sciences, University of Benin, Prof. Isaiah Ibeh, on Tuesday announced the development of a new drug that can cure HIV and AIDS.
Ibeh told the News Agency of Nigeria in Benin, the Edo State capital, that the herbal drug had undergone “a series of successful tests.”
The University Public Relations Officer, Harrison Osarenren, confirmed the story to our correspondent in a telephone interview on Tuesday.
He said the professor had found the solution. “The professor just developed a drug that can cure HIV/AIDS and it has been tested. He has solution to AIDS.”
Ibeh told NAN, “We are at the threshold of making history, in the sense that we seem to have with us something that will permanently take care of what over time seems to have defied all solutions.
“We are talking about the latest discovery of an oral drug made from plants extraction in Nigeria for the possible cure for the pandemic, HIV and AIDS virus.’’
According to him, research on the project was started in 2010 and culminated in the development of
“Deconcotion X (DX)–Liquid or Bioclean 11 for the cure of HIV and AIDS.”
Ibeh added, “The existing retroviral drugs are intervention drugs for the management of AIDS but our new discovery is a possible cure. We have tried to look at the product first; its toxicological analysis and discovered that it has a large safety margin.
“This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure.
“It also helped us to know the quantity we can conveniently give to animals and will feel secure that nothing untoward will happen.
“We have also done the bacteriological analysis on it, after which we looked at its effect on the virus and the result was quite revealing and refreshing.’’
Ibeh also said that the drug had been exposed to series of medical examination both in Nigeria and in the USA. He added that the drug had performed well on patients with the HIV virus and had shown evidence of total restoration of damaged tissues.
He said, “The result showed an increase in the body weight of the individual administered with DX.
“The body weight was statistically significant when compared with the control group.’’ He said that further tests were being conducted to determine “at what point will a patient become negative after being administered the drug?”
He said, “This verification is necessary because it is what is used to measure whether infection is still there or not. So we need to know the siro-convention time.
“But preliminary results showed that of the five latest patients orally administered with the drugs, our findings is that up to seven months three of them were siro negative while two were still faintly positive.’’ Ibeh appealed for support from the Federal Government and relevant bodies to assist the university with relevant equipment to sustain the research.